Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Thu, 11.08.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 11 August 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 19% to EUR 106.8 million in the first half of the year. At EUR 15.4 million, net income was down on the same period of the previous year, in which the sale and associated deconsolidation of the tumor irradiation device division  [ … ]
Technical analysis
To the publication
Thu, 11.08.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 11 August 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 19% to EUR 106.8 million in the first half of the year. At EUR 15.4 million, net income was down on the same period of the previous year, in which the sale and associated deconsolidation of the tumor irradiation device division  [ … ]
Technical analysis
To the publication
Thu, 04.08.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European consortium of research and industry partners, was selected to receive grants worth approximately 17 million Euro for the development of its medical countermeasure (MC [ … ]
Technical analysis
To the publication
Thu, 04.08.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European consortium of research and industry partners, was selected to receive grants worth approximately 17 million Euro for the development of its medical countermeasure (MC [ … ]
Technical analysis
To the publication
Wed, 27.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Insider information pursuant to Article 17 MA   Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter Berlin, 27 July 2022. Based on initial, unaudited assessments, revenues of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) for the second quarter increased by 26% fr [ … ]
Technical analysis
To the publication
Wed, 27.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Insider information pursuant to Article 17 MA   Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter Berlin, 27 July 2022. Based on initial, unaudited assessments, revenues of Berlin-based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) for the second quarter increased by 26% fr [ … ]
Technical analysis
To the publication
Thu, 21.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 21 July 2022. Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX), has announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their contract to advance the development of the new chemical en [ … ]
Technical analysis
To the publication
Thu, 21.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 21 July 2022. Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX), has announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, extended their contract to advance the development of the new chemical en [ … ]
Technical analysis
To the publication
Wed, 20.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 20 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225. This gives PRECIRIX priority access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225, which is used for the labeling of trial drugs in radionuclide  [ … ]
Technical analysis
To the publication
Wed, 20.07.2022       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 20 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225. This gives PRECIRIX priority access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225, which is used for the labeling of trial drugs in radionuclide  [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.